Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaires Citrone, Simons Buy Stakes in, Inc. (AMZN), Facebook Inc (FB), and Priceline Group Inc (PCLN)

Page 1 of 2

Billionaires Rob Citrone and Jim Simons are in harmony as far as the future prospects of, Inc. (NASDAQ:AMZN), Facebook Inc (NASDAQ:FB), Priceline Group Inc (NASDAQ:PCLN), and Horizon Pharma PLC (NASDAQ:HZNP) are concerned. The above companies were added to the portfolios of both Discovery Capital Management and Renaissance Technologies during the first quarter.

Discovery Capital Management

Rob Citrone worked as a portfolio manager at Fidelity Investments and Tiger Management before he established Discovery Capital in 1999. The fund’s annualized returns since its inception hover around 17%.

Simons’ Renaissance Technologies uses high frequency trading to exploit market inefficiencies. The fund charges particularly high fees of 36% for its exceptional returns owing to large transaction costs that go hand-in-hand with its trading strategy.

Why are we interested in the 13F filings of a select group of hedge funds? We use these filings to determine the top 15 small-cap stocks held by these elite funds based on 16 years of research that showed their top small-cap picks are much more profitable than both their large-cap stocks and the broader market as a whole. These small-cap stocks beat the S&P 500 Total Return Index by an average of nearly one percentage point per month in our backtests, which were conducted over the period of 1999 to 2012. Moreover, since the beginning of forward testing from August 2012, the strategy worked just as our research predicted, outperforming the market every year and returning 144% over the last 32 months, which is more than 84 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).

While Simons acquired some 1.15 million shares of, Inc. (NASDAQ:AMZN) valued at $428.98 million during the first quarter, Citrone initiated his own long position of 240,800 shares in addition to a call position on 500,000 shares of, Inc. (NASDAQ:AMZN) worth about $89.60 million and $186.05 million respectively. The $200.98 billion e-commerce giant is up by a staggering 39.1% year-to-date. Amazon has been under scrutiny for avoiding taxes in European countries by funneling its sales through low-tax Luxembourg. The company has given in to the pressure and has started booking revenue in individual European countries starting on May 1. Other prominent stockholders of, Inc. (NASDAQ:AMZN) are Ken Fisher‘s Fisher Asset Management and Boykin Curry’s Eagle Capital Management with 2.47 million and 2.23 million shares respectively.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!